Reporting owner · CIK 0001866174

Walsh Colin

SEC Form 4 history across 1 companies, 35 transactions and 1 filings.

DIRAttovia Therapeutics, Inc.
Open-market transaction mix26% buys8 buys · 23 sales
Latest filingAug 28, 2026, 09:38 PM

Available history · Aug 05, 2026 – Aug 06, 2026

Filings1Form 4 records
Buying$12.5M8 purchases
Selling$2.3M23 sales
Net value$10.3MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Walsh Colin transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyDerivative securityAmended filingSEC filing ↗$121kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyDerivative securityAmended filingSEC filing ↗$242kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyDerivative securityAmended filingSEC filing ↗$969kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyDerivative securityAmended filingSEC filing ↗$243kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyDerivative securityAmended filingSEC filing ↗$609kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyDerivative securityAmended filingSEC filing ↗$60.9kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRC · unknownDerivative securityAmended filingSEC filing ↗$0View disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRC · unknownDerivative securityAmended filingSEC filing ↗$0View disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRP · buyAmended filingSEC filing ↗$8.50MView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRC · unknownAmended filingSEC filing ↗$0View disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRC · unknownAmended filingSEC filing ↗$0View disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$1.60MView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$146kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$2.19kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$25.8kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$15.4kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$4.41kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$9.64kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$6.25kView disclosure →
ATTOAttovia Therapeutics, Inc.
Walsh ColinDIRS · saleAmended filingSEC filing ↗-$22.9kView disclosure →
Open a transaction for shares, transaction date, ownership and the original SEC filing.

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

buy at Attovia Therapeutics, Inc. on Aug 06, 2026 valued at $8,500,000.

Review SEC filing
Latest buy

buy at Attovia Therapeutics, Inc. on Aug 06, 2026 valued at $8,500,000.

Review SEC filing
Latest sale

sale at Attovia Therapeutics, Inc. on Aug 05, 2026 valued at $1,607,835.

Review SEC filing

Monthly open-market activity

Last 1 reported months · purchases and sales

View exact monthly values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 2026823$12,533,073.84$2,251,657.70$10,281,416.14

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$476.9K
Median P/S size$25.8K
Direct0
Indirect35
Aug 06, 2026unknown

Filing-only signals

Deterministic matches in this insider's history

Amended Filingfiling-context35Cluster Buypattern8Cluster Sellingpattern23Delayed Filingfiling-context35Derivative Transactionfiling-context8Director Buyrole8Large Buysize3Large Holdings Increaseholdings6Large Salesize5Repeat Buyerpattern7Repeat Sellerpattern18

Associated companies

Companies in the disclosed reporting history

Attovia Therapeutics, Inc.ATTO · 35 transactions · latest Aug 28, 2026, 09:38 PM

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

27 observations · Aug 5, 2026 – Aug 6, 2026. Window ends at the latest available report, not today.

Selected observation · Aug 6, 20263,020,632 shares reportedAmended filing
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 5, 202685,000Aug 28, 2026Amended transaction
Aug 5, 202684,012Aug 28, 2026Amended transaction
Aug 5, 202683,565Aug 28, 2026Amended transaction
Aug 5, 202682,233Aug 28, 2026Amended transaction
Aug 5, 202682,033Aug 28, 2026Amended transaction
Aug 5, 202680,477Aug 28, 2026Amended transaction
Aug 5, 202677,075Aug 28, 2026Amended transaction
Aug 5, 202676,875Aug 28, 2026Amended transaction
Aug 5, 202676,395Aug 28, 2026Amended transaction
Aug 5, 202676,295Aug 28, 2026Amended transaction
Aug 5, 202675,542Aug 28, 2026Amended transaction
Aug 5, 202674,870Aug 28, 2026Amended transaction
Aug 5, 202667,900Aug 28, 2026Amended transaction
Aug 5, 202667,500Aug 28, 2026Amended transaction
Aug 5, 202666,320Aug 28, 2026Amended transaction
Aug 5, 202665,280Aug 28, 2026Amended transaction
Aug 5, 202664,980Aug 28, 2026Amended transaction
Aug 5, 202664,537Aug 28, 2026Amended transaction
Aug 5, 202664,337Aug 28, 2026Amended transaction
Aug 5, 202663,637Aug 28, 2026Amended transaction
Aug 5, 202662,474Aug 28, 2026Amended transaction
Aug 5, 202662,374Aug 28, 2026Amended transaction
Aug 5, 202655,611Aug 28, 2026Amended transaction
Aug 5, 20260Aug 28, 2026Amended transaction
Aug 6, 20262,042,134Aug 28, 2026Amended transaction
Aug 6, 20262,520,632Aug 28, 2026Amended transaction
Aug 6, 20263,020,632Aug 28, 2026Amended transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Walsh Colin Insider Activity FAQ

SEC Form 4 context

Who is Walsh Colin?

Walsh Colin is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001866174.

Which companies has Walsh Colin reported transactions for?

Attovia Therapeutics, Inc.

When was Walsh Colin's latest insider buy?

buy at Attovia Therapeutics, Inc. on Aug 06, 2026 valued at $8,500,000.

When was Walsh Colin's latest insider sale?

sale at Attovia Therapeutics, Inc. on Aug 05, 2026 valued at $1,607,835.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.